Clinical trials: Epirubicin
Breast Cancer
Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors
The purpose of this randomized Phase III study is to determine whether preoperative focused microwave heat treatment and chemotherapy combined are more effective than preoperative chemotherapy alone in the treatment of large…
- Trial name
- Medifocus301 (NCT01204801)
- Testing
- Focused Microwave Thermotherapy, Chemotherapy (control)
- Where
- 2 sites in United States, Canada
- Volunteers
- 238 people
- Sponsor
- Medifocus, Inc.
Breast Cancer
Pyrotinib in Breast Cancer Patients With Poor Response to the Neoadjuvant Treatment of Trastuzumab and Pertuzumab
Pathological complete remission (pCR) after neoadjuvant therapy in HER2-positive early breast cancer patients is closely related to disease-free survival (DFS) and overall survival (OS), which makes pCR an important evaluation…
- Trial name
- PRETTY (NCT04255056)
- Testing
- Pyrotinib
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Sun Yat-sen University
Breast Cancer
Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer
This is a prospective Belgian, multi-center, open-label, single-arm phase II study of weekly paclitaxel at a dose of 80mg/m² in combination with weekly carboplatin (AUC=2), for 12 weeks, followed by 4 cycles of dose dense…
- Trial name
- NCT04224922
- Testing
- Paclitaxel, Carboplatinum, Epirubicin
- Where
- 18 sites in Belgium
- Volunteers
- 63 people
- Sponsor
- Universitair Ziekenhuis Brussel
Breast Cancer
Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer
To date no targeted agents are available to treat TNBC. Therefore chemotherapy is the only treatment option. TNBC often has a high amount of tumour infiltrating lymphocytes.
- Trial name
- GeparNuevo (NCT02685059)
- Testing
- MEDI4736 (Anti PD-L1), nab-Paclitaxel, Epirubicin
- Where
- Germany
- Volunteers
- 174 people
- Sponsor
- GBG Forschungs GmbH
Breast Cancer
Efficacy and Safety of DLBS1425 as Neoadjuvant in Stage II or III Breast Cancer Patients
This is a 2-arm, randomized, double-blind, placebo-controlled study aiming to determine the efficacy and safety of DLBS1425 in combination with anthracyclin-based regimen as a neoadjuvant therapy in subjects with previously…
- Trial name
- NCT01433562
- Testing
- DLBS1425
- Where
- Indonesia
- Volunteers
- 40 people
- Sponsor
- Dexa Medica Group
Breast Cancer
Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer
The goal of this clinical research is to learn if RAD001 given in combination with chemotherapy will turn off the signaling pathway (a chain of information that tells cancer cells to grow quickly) and make the chemotherapies…
- Trial name
- NCT00499603
- Testing
- Paclitaxel, 5-Fluorouracil, Epirubicin
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- M.D. Anderson Cancer Center
Gastric Cancer, Gastric Adenocarcinoma
Phase II Study With Catumaxomab in Patients With Gastric Cancer After Neoadjuvant CTx and Curative Resection
Primary evaluation of the safety, tolerability and feasibility regarding specific postoperative complications of an adjuvant treatment with catumaxomab administered after curative tumor resection subsequent to a neoadjuvant…
- Trial name
- NCT00464893
- Testing
- Catumaxomab
- Where
- 4 sites in Austria, Germany and 2 more
- Volunteers
- 70 people
- Sponsor
- Neovii Biotech
Breast Neoplasms
To Determine the Objective Response Rate of 4 Cycles of Docetaxel + Anthracycline (Epirubicin or Doxorubicine) Followed by 4 Cycles of Docetaxel Single Agent
To determine the Objective Response Rate of 4 cycles of docetaxel + anthracycline (epirubicin or doxorubicine) followed by 4 cycles of docetaxel single agent.
- Trial name
- NCT00620100
- Testing
- Docetaxel
- Where
- 2 sites in Austria, Poland
- Volunteers
- 2 people
- Sponsor
- Sanofi
Breast Cancer
Proteomic Signature in Breast Cancer: Correlation With Tumor Response to Neo-adjuvant Chemotherapy
The scope of the trial is to identify proteomic signatures correlated with tumor response to neo-adjuvant chemotherapy.
- Trial name
- SPAM (NCT00911911)
- Testing
- Blood sampling, BIOPSY, SURGERY
- Where
- 5 sites in France
- Volunteers
- 66 people
- Sponsor
- Centre Oscar Lambret
Breast Cancer
Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer
Triple-negative breast cancer (TNBC) is as sociated with shorter overall survival than other breast cancer subtypes, despite the use of curative-intent anthracycline- and taxane-based systemic chemotherapy.
- Trial name
- PRISM-TNBC (NCT06802757)
- Testing
- Posaconazole, Nab-paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Shandong Cancer Hospital and Institute
Early Breast Cancer, Neoadjuvant Therapy
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer
This study will look at the efficacy and safety of QL1706 plus albumin-bound paclitaxel followed by AC/EC in a neoadjuvant setting, in high-risk, ER+/HER2- early breast cancer.
- Conditions
- Early Breast Cancer, Neoadjuvant Therapy, HR+HER2- Breast Cancer
- Trial name
- QUEEN-Neo (NCT06404463)
- Testing
- QL1706 (bispecific antibody targeting PD-1 and CLTA-4), Albumin-bound paclitaxel, Doxorubicin
- Volunteers
- 76 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma
The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
To compare the impact on recurrence risk of adjuvant TAI and adjuvant TACE for patients with HCC and PVTT after hepatectomy.
- Trial name
- NCT03192644
- Testing
- TAI, TACE, epidoxorubicin and cisplatin and lipiodol
- Where
- China
- Volunteers
- 162 people
- Sponsor
- Sun Yat-sen University
Triple-negative Breast Cancer
Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy
Objective to evaluate the efficacy and safety of neoadjuvant therapy with Chidamide combined with chemotherapy for stage II - III triple-negative breast cancer，and to compare the efficacy and safety of chemotherapy with Chidamide…
- Trial name
- NCT04582955
- Testing
- Chidamide in combination with chemotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma
Risk Factors for the Leakage of Anticancer Drugs to Systemic Circulation by Transcatheter Arterial Chemoembolization
Hepatocellular carcinoma (HCC) is the most common malignant tumor of the liver. Transcatheter arterial chemoembolization (TACE) is the traditional method for the palliative management of patients with HCC.
- Trial name
- NCT00630240
- Where
- Taiwan
- Volunteers
- 53 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
HER2-Negative Locally Advanced Breast Cancer
Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer
A Prospective, Multicenter, Randomized Controlled Phase II Study to Evaluate the Efficacy and Safety of Adebrelimab Combined with Chemotherapy with or without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally…
- Trial name
- NCT06908668
- Testing
- Neoadjuvant Chemotherapy Combined with Immunotherapy and Radiotherapy, Neoadjuvant Chemotherapy Combined with Immunotherapy
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Breast Cancer
Docetaxel/Epirubicin/Bevacizumab as First Line Therapy for Metastatic HER2 Negative Breast Cancer
This study will evaluate the efficacy and toxicity of docetaxel-epirubicin combination plus bevacizumab as first line treatment in patients with metastatic and HER2 negative breast cancer.
- Trial name
- NCT00705315
- Testing
- Docetaxel, Epirubicin, Bevacizumab
- Where
- 10 sites in Greece
- Volunteers
- 46 people
- Sponsor
- Hellenic Oncology Research Group
Bladder Cancer
Optimal Adjuvant Intravesical Therapy for Intermediate Risk Non Muscle Invasive Bladder Cancer: A Randomized Controlled Trial
The objective of this prospective, single-center randomized controlled trial is to identify the optimal adjuvant intravesical therapy in patients with intermediate risk (IR) non muscle invasive bladder cancer by comparing two…
- Trial name
- NCT05146635
- Testing
- Intravesical Bcg, Intravesical chemotherapy (epirubicin)
- Where
- Egypt
- Volunteers
- 110 people
- Sponsor
- Mansoura University
Breast Cancer
ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer
Trial for the optimization of risk assessment and therapy success prediction in patients with early breast cancer by the use of biomarkers in advance to therapy decision-making to personalize therapies.
- Trial name
- ADAPT (NCT01779206)
- Testing
- Epirubicin, Cyclophosphamide, Docetaxel
- Where
- 2 sites in Germany
- Volunteers
- 4,936 people
- Sponsor
- Women's Cancer Study Group GmbH
Localized Hepatocellular Carcinoma
STOPPER CHINA:With Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma
A Single-arm Trial of Transcatheter Arterial Chemoembolization with Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma
- Trial name
- NCT03113955
- Testing
- Tandem Microsphere loaded with Epirubicin
- Where
- 10 sites in China
- Volunteers
- 109 people
- Sponsor
- Varian Medical Systems
Breast Cancer
Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
The goal of this clinical trial is to compare trastuzumab deruxtecan (T-DXd) to standard preoperative treatment in patients with non-metastatic HER2-positive breast cancer.
- Trial name
- ARIADNE (NCT05900206)
- Testing
- Trastuzumab deruxtecan, Docetaxel, Paclitaxel
- Where
- 7 sites in Sweden
- Volunteers
- 370 people
- Sponsor
- Karolinska University Hospital